Conference Call with Ajanta Pharma Management and Analysts on Q2FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ajanta Pharma announced Q2FY26 results Revenue from operations at Rs 1,354 crore against Rs 1,187 crore; up 14%. EBITDA at Rs 328 crore against Rs 311 crore; EBITDA at 24%; up 5%. Profit after tax at Rs 260 crore against Rs 216 crore; PAT at 19%; up 20%. The mark-to-market forex loss stood at Rs 41 crore Excluding this impact, EBITDA stood at Rs 369 crore, reflecting a 9% growth, with an EBITDA margin of 27%. PAT grew by 23%, with a PAT margin of 22%. Result PDF